APRIL 15, 2011 -- PART 1: ACHIEVEMENTS OF THE PAST YEAR
The second Sage Bionetworks Commons Congress will be held in San Francisco on April 15-16, 2011. The theme will be the move towards personalized, patient-driven medicine, and the role that Sage Bionetworks can play in that transition. Expect reports from the Sage Federation, Working Groups, and exciting projects like SageCite, poster sessions and evening activities.
A patient perspective on healthcare followed by summaries of the new projects that have emerged since the 2010 Congress as a demonstration that the efforts of the Commons over the past year have paid off. The Federation, the Commons Platform, Repository and independent projects like SageCite will be featured. Sage Bionetworks will review its own internal development work and a new journal for sharing models will be announced.
Mariano Alvarez, Columbia University
Atul Butte, MD, PhD is Chief of the Division of Systems Medicine and Associate Professor of Pediatrics, Medicine, and by courtesy, Computer Science, at Stanford University and Lucile Packard Children's Hospital. Dr. Butte trained in Computer Science at Brown University, worked as a software engineer at Apple and Microsoft, received his MD at Brown University, trained in Pediatrics and Pediatric Endocrinology at Children's Hospital Boston, then received his PhD in Health Sciences and Technology from Harvard Medical School and MIT.
Xudong Dai, Sage Bionetworks.
Jonathan Derry is Vice President of Research at Sage Bionetworks.
President, Co-Founder and Director of Sage Bionetworks. Dr. Friend is the President of Sage Bionetworks. He is an authority in the field of cancer biology and a leader in efforts to make large scale, data-intensive biology broadly accessible to the entire research community. Dr. Friend has been a senior advisor to the NCI, several biotech companies, a Trustee of the AACR and is a AAAS and Ashoka Fellow as well as an editorial board memeber of Open Network Biology. Dr. Friend was previously Senior Vice President and Franchise Head for Oncology Research at Merck & Co., Inc. where he led Merck’s Basic Cancer Research efforts. Prior to joining Merck, Dr. Friend was recruited by Dr. Leland Hartwell to join the Fred Hutchinson Cancer Research Center’s Seattle Project, an advanced institute for drug discovery. While there Drs. Friend and Hartwell developed a method for examining large patterns of genes that led them to co-found Rosetta Inpharmatics in 2001. Dr. Friend has also held faculty positions at Harvard Medical School from 1987 to 1995 and at Massachusetts General Hospital from 1990 to 1995. He received his B.A. in philosophy, his Ph.D. in biochemistry and his M.D. from Indiana University.
Gregory Hannum is a graduate student at the University of California, San Diego.
Hyunseok Peter Kang
Hyunseok Peter Kang is a Postdoctoral Research fellow, Biomedical Informatics (IDP).
Peter Kapitein is President and patient advocate of inspire2live.
Michael M. Kellen currently serves as vice chairman of Arnhold and S. Bleichroeder Advisers, LLC and as co-president and co-chief executive officer of Arnhold and S. Bleichroeder Holdings, Inc. Kellen is on the Board of Trustees at the Cancer Research Institute.
Dr. Liz Lyon is the Director of UKOLN at the University of Bath UK, where she leads work to promote synergies between digital libraries and open science environments.
Lara Mangravite is Sr. Scientist of Systems Biology at Sage Bionetworks.
Brig Mecham, PhD is a Postdoctoral Researcher at Sage Bionetworks Development.
Eric Schadt, PhD, is Director of the Icahn Institute for Genomics and Multiscale Biology, Chair of the Department of Genetics and Genomics Sciences, and the Jean C. and James W. Crystal Professor of Genomics at the Icahn School of Medicine at Mount Sinai. Dr. Schadt is an expert on the generation and integration of very large-scale sequence variation, molecular profiling and clinical data in disease populations for constructing molecular networks that define disease states and link molecular biology to physiology. He has published more than 200 peer-reviewed papers in leading scientific journals, and contributed to a number of discoveries relating to the genetic basis of common human diseases such as diabetes, obesity, and Alzheimer’s disease. Dr. Schadt is also a founding member of Sage Bionetworks, an open-access genomics initiative designed to build and support databases and an accessible platform for creating innovative dynamic disease models. Prior to joining Mount Sinai in 2011, he was Chief Scientific Officer at Pacific Biosciences, the next-generation sequencing technology provider. Previously, Dr. Schadt was Executive Scientific Director of Genetics at Rosetta Inpharmatics, a subsidiary of Merck & Co., Inc. in Seattle, and before Rosetta, Dr. Schadt was a Senior Research Scientist at Roche Bioscience. He received his B.A. in applied mathematics and computer science from California Polytechnic State University, his M.A. in pure mathematics from University of California, Davis, and his Ph.D. in bio-mathematics from University of California, Los Angeles (requiring Ph.D. candidacy in molecular biology and mathematics).